Skip to main content
Fig. 4 | Eye and Vision

Fig. 4

From: Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy

Fig. 4

Protein changes of (a) Kir4.1, (b) AQP4, (c) GS, and (d) GFAP in diabetic rat retinas treated with or without ranibizumab. e Co-immunostaining of Kir4.1 and GFAP in 12-week diabetic rat retinas (Kir4.1, green; GFAP, red; DAPI, blue), scale bar: 20 μm. Data are expressed as mean ± SE (n = 7, *P < 0.05). Quantification of fluorescence intensities of Kir4.1 (f, n = 5, *P < 0.05) and GFAP (g, n = 3, *P < 0.05) among three groups. N: normal control; D: 12-week diabetic retina; D + R: diabetic rat treated with ranibizumab

Back to article page